Screener
Neurocrine Biosciences NBIX Net gains (losses) on investments
Net gains (losses) on investments at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Neurocrine Biosciences in its filing.
Tagged under the XBRL concept us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss.
The source filing: Neurocrine Biosciences’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000914475-26-000026
| (in millions, except per share data) | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Total operating expenses | 621.1 | 549.0 |
| Operating income | 193.4 | 23.6 |
| Other income (expense): | ||
| Unrealized gain (loss) on equity investments | 25.3 | (30.6) |
| Investment income and other, net | 28.1 | 21.7 |
| Total other income (expense), net | 53.4 | (8.9) |
| Income before provision for income taxes | 246.8 | 14.7 |
| Provision for income taxes | 48.9 | 6.8 |
Item 1. Financial Statements
FAQ
- What is Neurocrine Biosciences's net gains (losses) on investments?
- Neurocrine Biosciences (NBIX) reported net gains (losses) on investments of $25.3M in Q1 2026.
- How has Neurocrine Biosciences's net gains (losses) on investments changed year-over-year?
- Neurocrine Biosciences's net gains (losses) on investments increased by 182.7% year-over-year, from -$30.6M to $25.3M.
- What is the long-term trend for Neurocrine Biosciences's net gains (losses) on investments?
- Over 3 years (2021 to 2024), Neurocrine Biosciences's net gains (losses) on investments has grown at a 21.1% compound annual growth rate (CAGR), from $20.9M to -$37.1M.
- What does net gains (losses) on investments mean?
- Realized and unrealized gains/losses on investments removed from operating cash flow since they're investing-related.
Ask your AI about Neurocrine Biosciences's net gains (losses) on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude